Trastuzumab Deruxtecan Garners Approval in Japan for HER2-Low Metastatic Breast Cancer

Japan’s Ministry of Health, Labor and Welfare has approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2-low unresectable or recurrent breast cancer after prior chemotherapy.

Related Keywords

Japan ,Wataru Takasaki ,Daiichi Sankyo ,Japan Ministry Of Health ,Rd Division ,Trastuzumab Deruxtecan ,Her2 Low Metastatic Breast Cancer ,Phase 3 Destiny Breast04 Trial ,Japans Ministry Of Health ,Labor And Welfare ,